SupplementaryTables.docx (172.45 kB)
Download fileSystematic literature review and network meta-analysis of pembrolizumab versus other interventions for previously untreated, unresectable or metastatic, microsatellite instability-high or mismatch repair deficient colorectal cancer - Supplementary Tables
dataset
posted on 2022-03-25, 12:20 authored by Hark Jin, Mayur Amonkar, Raquel Aguiar-Ibáñez, Manasi Thosar, Monica Chase, Sam KeepingTable S1: Search strategy for Embase
Database: Embase 1974 to July 12, 2019
Search executed on July 15, 2019
Table S2: Search strategy for MEDLINE
Databases: Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Daily and Versions(R) 1946 to July 12, 2019
Search executed on July 15, 2019
Table S3: Search strategy for CENTRAL
Database(s): EBM Reviews - Cochrane Central Register of Controlled Trials October 2019
Search executed on July 15, 2019
Table S4: Search strategy for Embase - Update
Database: Embase 1974 to April 27, 2020
Search executed: April 28, 2020
Table S5: Search strategy for MEDLINE
Databases: Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Daily and Versions(R) 1946 to April 27, 2020
Search executed: April 28, 2020
Table S6: Search strategy for CENTRAL
Database(s): EBM Reviews - Cochrane Central Register of Controlled Trials March 2020
Search executed on April 28, 2020
Table S7: Eligibility criteria from trials included in systematic review
Table S8: Patient characteristics from trials included in systematic review
Table S9: Outcomes from trials included in systematic review
Table S10: Proportional hazard assumption test (Grambsch and Therneau test) of trials included in the analysis
Table S11: Estimated constant hazard ratios of overall survival with pembrolizumab versus competing interventions from fixed-effect and random-effects network meta-analysis; no adjustment for crossover in KEYNOTE-177
Table S12: Estimated constant hazard ratios of overall survival with pembrolizumab versus competing interventions from fixed-effect and random-effects network meta-analysis; adjustment for crossover in KEYNOTE-177 using 2-stage model
Table S13: Estimated constant hazard ratios of overall survival with pembrolizumab versus competing interventions from fixed-effect and random-effects network meta-analysis; adjustment for crossover in KEYNOTE-177 using RPSFT model
Table S14: Estimated constant hazard ratios of progression-free survival with pembrolizumab versus competing interventions from fixed-effect and random-effects network meta-analysis
Table S15: Estimated time-varying hazard ratios of overall survival with pembrolizumab versus competing interventions from random-effect network meta-analysis; adjustment for crossover in KEYNOTE-177 using RPSFT model
Table S16: Odds ratios estimated from fixed-effect network meta-analysis for treatment-related Grade 3+ adverse events
